‡a
Author's Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
‡a
Author's Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting
‡a
clinicalutilityofcyp2c19genotypeguidedantiplatelettherapyinpatientsatriskofadversecardiovascularandcerebrovasculareventsareviewofemergingevidence
‡A
Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
‡9
1
‡a
frequencyandclinicaloutcomesofcyp2c19genotypeguidedescalationanddeescalationofantiplatelettherapyinarealworldclinicalsetting
‡A
Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting
‡9
1